Please ensure Javascript is enabled for purposes of website accessibility

FDA Authorizes Roche's Coronavirus Antibody Test

By Taylor Carmichael – Updated May 8, 2020 at 5:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The new diagnostic tool measures whether a person has developed antibodies for SARS-CoV-2.

On Monday, the Food and Drug Administration granted an emergency use authorization to Roche (RHHBY -1.65%) for its COVID-19 diagnostic test. The test, which is intended to be given to people who have already been confirmed to have the disease, measures whether a patient's immune system has started developing antibodies for SARS-CoV-2. The idea is to find the people who might have developed an immunity to the coronavirus.

The diagnostic is meant to exclude antibodies that your immune system creates to fight other coronaviruses (like the common cold). Based on a measurement of 5,272 samples, Roche's diagnostic found antibodies at a 100% rate, and was 99.81% accurate in distinguishing SARS-CoV-2 antibodies from other antibodies.  

blood test COVID-19

Image source: Getty Images

It's a crowded market.

When the pandemic escalated back in March, the FDA decided to relax its traditional oversight function over antibody tests in order to increase the speed at which they could be brought to market. This was done because of the emergency nature of this threat, and because antibody tests are not used to determine whether someone has COVID-19.

As a result, the market has been flooded with more than 200 SARS-CoV-2 antibody tests. Yet the FDA has only authorized 12 such tests. When Roche reported its earnings in April, CEO Severin Schwan did not mince words about the other antibody tests on the market. "It's a disaster," he said. "These tests are not worth anything, or have very little use." 

On the same day as it authorized Roche's new diagnostic, the FDA also issued more stringent rules for SARS-CoV-2 antibody tests. The agency is now requiring that all antibody diagnostics for the coronavirus must obtain explicit FDA authorization within 10 days of being on the market.  


Taylor Carmichael has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Roche Holding Ltd. (ADR) Stock Quote
Roche Holding Ltd. (ADR)
$41.73 (-1.65%) $0.70

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.